Implantation of pacemakers, especially multi-lead systems, is performed increasingly often. Leads located inside the veins chronically irritate the vascular wall inducing an inflammatory response causing neointima overgrowth and thrombosis, and leading to vessel lumen narrowing or even occlusion. It is observed in ~45% of cases but causes clinical symptoms of vascular occlusion, including superior vena cava syndrome (SVCS), in only 0.35%-1.5% [1] [2] [3] . We present two cases of endovascular treatment of severe, symptomatic venous occlusion in patients with an implantable cardiac pacemaker. A Venovo  (Bard, Covington, GA, USA) self-expanding stent, dedicated for the venous system, was used in both cases. The procedures were performed by a multidisciplinary team in the hybrid angiography suite, using general anaesthesia and with full cardioanaesthetic and cardiosurgical support. Case 1: A 52-year-old patient who underwent biological mitral valve replacement in 2015 had a dual-chamber pacemaker (DDD) implanted for treatment of third-degree atrioventricular block. One year later the patient experienced left hand oedema, worsening his quality of life. Critical stenosis of the left brachiocephalic vein (BCV) and collaterals were found during phlebography (Fig. 1A) . The procedure was started with transvenous lead extraction (TLE). The stenoses were dilated with Atlas TM (Bard, Covington, GA, USA) 12/60 mm and 18/60 mm balloon catheters, and afterwards two overlapping Venovo  stents were implanted: 20/80 mm and 16/80 mm, covering the entire length of the stenosis. Two pacemaker leads were implanted through the stents providing DDD-stimulation ( Fig. 2A, B) . TLE was perfomed, followed by angioplasty of both BCVs was using Atlas TM 12/60 mm and 18/60 mm balloon catheters. A Venovo  16/140 mm stent was implanted into the left BCV and an Epic  (Boston Scientific, Marlborough, MA, USA) 14 × 40 mm stent was placed in the right BCV. Kissing-balloon angioplasty of stents was performed (Fig. 2C) . A subcutaneous defibrillation system was implanted. No complications were observed. In both cases, a vitamin K antagonist was initiated one day after the procedure. Both patients presented complete withdrawal of SVCS symptoms. No symptoms of restenosis were observed during 24-month follow-up (Figs. 1C, 2D) . The unique structure of the stents prevents them from being crushed between the clavicle and the first rib. The physiology of the venous system is less understood than the arterial system and remains a challenge to physicians, who use central veins increasingly often, with little thought about late complications. Surgical treatment of central venous pathologies is very difficult and endovascular treatment has been less effective. In our opinion, efficient and durable treatment is possible thanks to new venous-designed stents. There is an urgent need to build multidisciplinary, experienced teams consisting of electrocardiologists, sonographers, interventional radiologists, angiologists, cardiosurgeons, and anaesthesiologists. All procedures must be performed in the hybrid angiography suite, using all-modality guidance (ultrasound, transoesophageal echocardiography, fluoroscopy) and cardiosurgical support. 
